Amedisys price target raised to $100 from $97 at RBC Capital

RBC Capital raised the firm’s price target on Amedisys (AMED) to $100 from $97 and keeps an Outperform rating on the shares. The firm maintains its view that UnitedHealth Group (UNH) will complete its pending acquisition of the company despite the DOJ scrutiny around Optum as it sees comparatively less anti-competitive concern about vertical integration of UnitedHealth and Amedisys than about UnitedHealth’s acquisition of Change Healthcare, which the DOJ unsuccessfully attempted to block.